BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

NIGERIA’S pharmaceutical sector is hampered by import dependency and years of economic and infrastructural shocks. The ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of ...

GERMAN drug developer BioNTech has signed an agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) to manufacture ...

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Dividend stocks are a smart way to navigate an uncertain market. Besides generating steady passive income, dividend-paying ...

Could the world’s best-selling drug have competition on the way? American pharmaceutical giant Bristol Myers Squibb agreed ...